Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij(The Netherlands Cancer Institute), Ton N. Schumacher(Leiden University Medical Center), Pia Kvistborg(The Netherlands Cancer Institute), Marit M. van Buuren(The Netherlands Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center), Dris El Atmioui(The Netherlands Cancer Institute), Mireille Toebes(The Netherlands Cancer Institute), Henk Hilkmann(The Netherlands Cancer Institute), Ron Kerkhoven(The Netherlands Cancer Institute), Bianca Heemskerk(The Netherlands Cancer Institute), Michael R. Stratton(Wellcome Sanger Institute), Arno Velds(The Netherlands Cancer Institute), Sam Behjati(University of Cambridge), Can Keşmir(Utrecht University), Laura J. A. van Dijk(The Netherlands Cancer Institute), Marja Nieuwland(The Netherlands Cancer Institute), Daisy Philips(The Netherlands Cancer Institute)
Cited by 799
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
The cancer genome
|Nature|2009|3.5k
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
|Nucleic Acids Research|2014|2.4k